Lexaria Bioscience (LEXX) announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria’s patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension. C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000. As Chief Medical Advisor, Dr. Gibson will participate with other scientific and medical experts within Lexaria’s newly-formed scientific advisory board in pursuing Lexaria’s prioritized objectives in the fields of drug delivery optimization.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience Explores Oral Liraglutide Potential
- Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide
- Lexaria Bioscience files to sell 4.55M shares of common stock for holders
- Lexaria Bioscience’s Promising Outlook on GLP-1 Drugs
- Lexaria Bioscience’s Oral Tirzepatide Study Progresses